drugset / Trial / NCT02571140

A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) Formulations in Healthy Subjects

NCT02571140

Phase 1 Completed 30 enrolled Entera Bio Ltd.
Non-randomizedCrossoverOpen-labelTreatment

Summary

This study will have one stage consisting of multiple treatment visits. The study is designed to assess the safety and bioavailability of Entera's oral PTH(1 - 34) in adult male healthy volunteers in various formulation. The study is also designed to assess the reproducibility of pharmacokinetic profiles with various formulations.

Timeline

Start
2013-10
Primary completion
2017-08
Completion
2017-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Teriparatide Protein / enzyme biologic Subcutaneous
Subject Teriparatide Protein / enzyme biologic Oral

Indications

No indication recorded.